EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Donghyun Seo iD, Jun Hyeok Lim

International Journal of Molecular Sciences · 29.05.2024 · 25 (11) · 5917

DOI: 10.3390/ijms25115917 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.05.2024. Verfasst von Donghyun Seo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Exons. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inha University, INHA UNIVERSITY Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations. EGFR exon 20 insertions are less responsive to conventional tyrosine kinase inhibitors (TKIs), leading to the development of targeted agents. This review explores key therapeutic agents, such as Amivantamab, Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib, which have shown promise in treating NSCLC with EGFR exon 20 insertions. Amivantamab, a bispecific antibody-targeting EGFR and c-MET, demonstrates significant efficacy, particularly when combined with chemotherapy. Mobocertinib, a TKI, selectively targets EGFR exon 20 mutations but faces limitations in efficacy. Poziotinib, another oral TKI, shows mixed results due to mutation-specific responses. Zipalertinib and Sunvozertinib have emerged as potent TKIs with promising clinical data. Despite these advances, challenges in overcoming resistance mutations and improving central nervous system penetration remain. Future research should focus on optimizing first-line combination therapies and enhancing diagnostic strategies for comprehensive mutation profiling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsExonsProtein Kinase InhibitorsMolecular Targeted TherapyHumansMutagenesis, InsertionalMutationAntineoplastic Agents

Stichwörter der Autor:innen

EGFR exon 20 insertionamivantamabmobocertinibnon-small-cell lung cancerpoziotinibsunvozertinibtyrosine kinase inhibitorszipalertinib

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea.
  • Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea.

ORCID-Profile: Donghyun Seo

Förderung

  • Inha University
  • INHA UNIVERSITY Research Grant

Zitieren

APA

Seo, D., & Lim, J. H. (2024). Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 25(11), 5917. https://doi.org/10.3390/ijms25115917

Vancouver

Seo D, Lim JH. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 2024;25(11):5917. doi:10.3390/ijms25115917

BibTeX
@article{Seo2024,
  author = {Seo, Donghyun and Lim, Jun Hyeok},
  title = {Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {11},
  pages = {5917},
  doi = {10.3390/ijms25115917}
}
Kostenlos starten →